In its latest annual report, IQVIA showed that the 340B drug pricing program has continued to grow at double digit rates. In 2025, 340B drug sales grew by 20.3% year-over-year reaching $179.5B. If you adjust this data for missing 340B sales, IQVIA projects that the 340B program is “approximately $200B, which is approaching the size of Medicare Part D.” The report notes that “from January 2018 through December 2025, 340B purchases grew 232.8%, versus 71.3% for non-340B purchases”, and that 80% of the growth in 340B purchases is due to increased utilization. Meanwhile patients, who continue to pay 20% of ASP+6% for their 340B drug copayments and often pay more than the acquisition cost for the 340B drug, receive no benefit from the sizable discounts provided to intermediaries who in turn profiteer from the difference between their 340B acquisition price and the ASP+6% allowable Medicare price.